Tackling challenges in viral vector manufacturing

Though viral vectors are used extensively in cell and gene therapy, the challenges of manufacturing such complex biologics at commercial scale is still a limitation to its broader use. Dr. Eduard Ayuso discusses how DINAMIQS overcomes these challenges.

Read the article

Process optimization for viral vector manufacturing

Dr. Eduard Ayuso speaks about how upstream and downstream process optimization using design of experiments, a platform approach and end-to-end capabilities can tackle manufacturing challenges and help to expedite drug development.

Watch the webinar

Latest news

Update May 04, 2024
Celebrating 1 year as Siegfried DINAMIQS
Update Mar 01, 2024
DINAMIQS welcomes new CEO
Media release Feb 02, 2024
DINAMIQS Appoints New CEO and Board Member
Update Jan 18, 2024
DINAMIQS welcomes two new leadership team members
Update Dec 27, 2023
Newly launched website for Magic Horizon
Update Dec 19, 2023
Successful implementation of the Stunner
Update Dec 11, 2023
Implementing the SamuxMP mass photometer
Update Nov 06, 2023
We are open for partnerships
Update Sep 26, 2023
Setting up the AKTA Avant
Update Sep 21, 2023
Reaching a next milestone
Media release May 24, 2023
Siegfried acquires majority stake in DINAMIQS to establish a best-in-class development and manufacturing organization for cell and gene therapies
To top